## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.4% below STRENGTH zone (3.0-6.0%); PEG 1.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($111.41)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 4
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. L2 Asset Management LLC Grows Position in DaVita Inc. $DVA**
- Source: MarketBeat | 20251208T122907 | Neutral | Relevance: 98%
-  L2 Asset Management LLC significantly increased its stake in DaVita Inc. (NYSE:DVA) by 742.2% in the second quarter, now holding 29,528 shares valued at $4.21 million. This move aligns with other institutional investors, collectively owning about 90.1% of the shares, despite the company missing recent EPS expectations and analysts maintaining a cautious "Reduce" rating with a $148 target. DaVita's stock performance reflects this caution, trading at $117.41 and analysts anticipating 10.76 EPS for the current year.

**2. Norges Bank Makes New Investment in DaVita Inc. $DVA**
- Source: MarketBeat | 20251208T104627 | Neutral | Relevance: 97%
- Norges Bank has acquired a new position in DaVita Inc. (NYSE:DVA) during the second quarter, purchasing 231,565 shares valued at approximately $32.99 million. This makes Norges Bank the owner of 0.32% of DaVita's stock. Other institutional investors have also modified their holdings in the company, which recently reported Q3 earnings per share of $2.51, missing analyst estimates.

**3. Amundi Cuts Stock Holdings in DaVita Inc. $DVA**
- Source: MarketBeat | 20251209T081111 | Neutral | Relevance: 97%
-  Amundi reduced its stake in DaVita Inc. by 11.5% in the second quarter, bringing its total holdings to 458,331 shares valued at approximately $65.34 million. Wall Street analysts maintain a cautious outlook on DaVita, with an average "Reduce" rating and a price target of $148. The company recently missed its quarterly EPS estimates, reporting $2.51 against an expected $3.17, while revenue was largely in line with forecasts.

**4. Epoch Investment Partners Inc. Sells 399,500 Shares of DaVita Inc. $DVA**
- Source: MarketBeat | 20251207T111410 | Neutral | Relevance: 95%
-  Epoch Investment Partners Inc. significantly reduced its stake in DaVita Inc. (NYSE: DVA) by selling 399,500 shares, representing a 97.9% cut in the second quarter. Despite this, other major institutions like Norges Bank and Doma Perpetual Capital Management LLC increased their holdings, maintaining institutional ownership at around 90.12%. DaVita recently missed quarterly EPS estimates and has an average analyst rating of "Reduce" with a target price of $148.00.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 8.1 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 14.5% below SMA200.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.50 suggests fair value with growth premium. Forward P/E 9.2x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.3B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.50 |
| Forward P/E | 9.2 |
| Current P/E | 10.9 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -2.4% (minimal 5-day change). Below STRENGTH zone by 5.4pp (needs >3.0% for momentum thesis). Below SMA200 (0.85x), long-term trend not supportive.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.41% (CS: 32) | Weak |
| RSI_14 | 38.4 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 0.980x | Below |
| vs SMA50 | 0.946x | Below |
| vs SMA200 | 0.855x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $116.67
- **Stop Loss:** $111.41 (4.5% risk)
- **Target:** $121.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $6,650.19
- **Portfolio %:** 6.65%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*